Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sad - Yes, I agree. I think they will on license or give it back whilst retaining some royalties for their trouble.
Apologies waiting and not writing. Pred text.
Hi Potnak. As far as l know Sierra obtained Momoletonib from Gilead for 198m dollars. 3 million of which was paid upfront with a further 195 million in milestone payments. What with milestone payments for SRA737 that leaves them in a bit of a quandary. Lack of funding is root cause for lack of continued development. As for exploring options it would appear that writing to see/ on license Momelotinib to obtain funding for SARz737.
Regards
Yes, the data looks to be good and has been validated by some eminent scientists but IMO that isn't the issue. As yet, it hasn't been trialed in combo and it is going to cost a lot to do that with no guarantee of success. Just a guess, but say Dilly needs to find 500 million dollars to run trials and pay milestones just to prove efficacy, then they have to show enough of an improvement to push it for approval and pay more milestones. It's a big gamble and IMO the main reason they haven't done anything yet. This is what Dilly means when he says giving it deep thoughts. I reckon he was hoping for a big lift on the back of Momo so he could raise for 737 and it hasn't happened.
Potnak, I fear that Momo was the wrong horse to be backed by Sierra but they ha nothing else that had progressed to that stage of development. I feel that SRA 737 will prevail, but just wish they would get on with it, rather than Dillying around.
Yes, I think there is some truth in that. I believe we will have had offers but they probably didn't come near to what Tim and the board think the fair value is. Covid might blow the doors off 1801 and then they will have to pay it. 737 might be a little insurance policy in case TYK2 goes awry. As I said, I'm excited.
Not sure about that. If the compounds are that good, I assume the Board would be keen and focused on early clinical trials so that they can achieve full value for what they think they are worth. Just another way of looking at it.
Baton - well she is the expert but I did say combo looks good so I agree with her. All I'm saying is, if SRA737 was a nailed on blockbuster, we wouldn't be having this conversation. Sierra are in a situation where they have to stump up a lot of money to see if it is a blockbuster if it isn't, it will finish them off regardless of if momo is going anywhere or not. I'm bullish for SAR and excited for what the next few months will bring but as Utar always points out. If our compounds were that good, we'd already have deals for them.
Last time I did a thorough google search on SRA737 trials I found some people discussing excitedly getting signed up for treatment with cancer. Unfortunately none of them had a success story with it. Admittedly it was a small handful of people who shared their experience and many may have benefited, I just didn't find anything positive posted about it by anyone that took part. Maybe its not as good as they hoped it would be. I'm bullish on sar generally but this was sobering to read and possibly explains why its deprioritised.
Tirpana Sen doesn't agree with you potnak.
Pronai, now Sierra did do a good job on pushing 737 through trials but some LTH here seem to forget that as trials progressed and data was collected it was shown it wasn't great as a mono therapy. The indications that Sierra aimed to target were reduced until we are where we are. What I'm saying is the compound isn't what Sierra first took on and all the anticipated developments and ways to fundraise had to be re examined. We shouldn't look at the compound through rose coloured specs. Sierra will have to find hundreds of millions of dollars to fund something that, If it failed would finish them off. With that said, The data for combo looks like it could be good so who knows. Not sticking up for Sierra but a bigger company might have already pulled the plug on it.
Yes remember reading why Sierra were chosen at the time as they were small and would carry it through faster Than a larger pharmaceutical company . Who would just sit on it ! Unfortunately that’s just what’s happened anyway GLA
Spot on. The word "shafted" springs to mind. A crap deal for Sareum from inception despite the fact that some of our money was involved in setting it up.
am intensely relaxed on 737.
ICR/CRT/CRUK have been in charge of the trials to date, and so have seen the data.
They are still paying their own time and money doing research (recent Wee1 combo paper at ICR (where SRRA paid expenses) ) by the trial leader Udai Bannerjee. And Paul Workman (CEO of ICR until last week and one of the top 5 cancer researchers globally). They wouldnt be putting their names to a duffer. Obviously has legs.
The Parp combo preclinical data is compelling.
The contract extension is an appendix to SRRA last form 10k and dated September.
I expect they were given a year. Its inevitable something will move (either vantalis/ wee1/ niraparib, or another Parp player. its a hot sector). and it will have to happen before September IMHO. As ever we wait. But Chk1 alone is a ten bagger when it happens and its not long IMHO. Or we get it back which is also good. (we got a free P1/2 trial)
I'd imagine if SRA737 continued with the radio silence for much longer, Dilly may well be headed the same way as Glover.
Unless he is sorting multiple deals/logistical nightmares, and is about to drop the mother of all announcements. If not, I cant imagine his shareholders being overly happy at the potential he's keeping from the world....
The scientific evidence for SRA737 in combination with other inhibitors started in earnest early to mid 2019. In two years Sierra has not moved anything forward for further trials or announced anything of how they might take it forward. In my opinion All it has done is hide it away and used Momelotinib as a smokescreen. It has not published the results of the Phase1/2 trials completed in March 2020 which breaches FDA criteria. The nearest they came to a trial was when they announced the intention to investigate SRA737 in combo with Merck’s Niraparib. And that was abruptly shelved with no reason given as far as I am aware
Working- think you are right. Must be a logistical nightmare. But he has certainly had enough time in my opinion to at least get the show on the road.
I should imagine Sierra will be under humungous pressure to advance Chk1 in some form or other given the information we have seen of late not least that Cancer Research went out of their way to do a presentation. With this in mind I think many non-for-profit organisation will also be probably on the FDA's case to potentially force them to move.
Looks like PF477736 is an ATP inhibitor owned by Pfizer. Seems to have been discontinued?
Could all these new findings be part of Sierras delay? Too many potentials out there and they’re trying to juggle partners
I know Dilly says it’s ‘in his back pocket’ for a rainy day, but might Sierra be trying to satisfy multiple pharmas all wanting to use SRA737?
An additional study in the same area using PF477736:
Dominant mutations in CHK1 cause pronuclear fusion failure and zygote arrest that can be rescued by CHK1 inhibitor
https://www.nature.com/articles/s41422-021-00507-8
ATB
Nice find Citizen. Might be an idea to wake up Dilley to tell him more good news for SRA737.
Morning all, the dust has certainly settled after yesterdays shenanigans, back to the research!
Posted a link a few months back, but SpringerLink have just published this:
Maternal heterozygous mutation in CHEK1 leads to mitotic arrest in human zygotes
https://link.springer.com/article/10.1007/s13238-021-00844-9
Our very own CCT244747 :)
"Our findings also imply the possibility to use low dosage CHEK1 inhibitor treatment to release cells from the low-level genome stress-induced cell cycle block during zygote mitosis or other sensitive periods.
In summary, our results revealed an unexpected zygote mitotic checkpoint, which is extremely sensitive to the CHEK1 kinase activity. The fine-tuning of the DNA damage checkpoint permits the arrested one-cell embryos to overcome the first mitotic block and develop into healthy animals. These findings have important implications in assisted human reproduction and genetic counseling in women with zygotic division failure."
ATB